Fundraising FoxNGN Capital — Full Portfolio
4 tracked investments · listed companies and verified rows first
Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases.
BiotechHealthtechMedical DevicesFort Collins, US
Peter Palese(Founder & Scientific Advisor)Adolfo García-Sastre(Founder & Scientific Advisor)Elliott Kieff(Founder & Scientific Advisor)William Wick(CEO, Board Member and Managing Director)
Co-investorsBay City Capital
Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.
BiotechHealthtechMedical DevicesWestminster, US
Andrew J. Tofe(Director)inBritt Pearson(Executive Officer)inJeff Marx(Executive Officer)inGlen Kashuba(Executive Officer, Director)inJerome Connor(Executive Officer)inAndrew Handwerker(Executive Officer)
Co-investorsRevelation PartnersOrbiMed
BiotechHealthtechCambridge, US
James McCullough(Executive Officer, Director)William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Sara Barrington(Executive Officer)
BoardJoseph Boystak(Director)inGeert-Jan Mulder(Director)in
Co-investorsArcus VenturesForbion
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.